38.2 USD
+3.4 (+9.77%)
37.7208 USD
-0.48 (-1.25%)
Taking everything into account, CORT scores 7 out of 10 in our fundamental rating. CORT was compared to 191 industry peers in the Pharmaceuticals industry. Both the health and profitability get an excellent rating, making CORT a very profitable company, without any liquidiy or solvency issues. CORT is showing excellent growth while it is valued at reasonable prices. Keep and eye on this one! With these ratings, CORT could be worth investigating further for growth and quality investing!.
1. Profitability
1.1 Basic Checks
CORT had positive earnings in the past year.
CORT had a positive operating cash flow in the past year.
CORT had positive earnings in each of the past 5 years.
Each year in the past 5 years CORT had a positive operating cash flow.
1.2 Ratios
With an excellent Return On Assets value of 12.88%, CORT belongs to the best of the industry, outperforming 92.67% of the companies in the same industry.
With an excellent Return On Equity value of 16.79%, CORT belongs to the best of the industry, outperforming 89.53% of the companies in the same industry.
CORT has a better Return On Invested Capital (8.69%) than 87.43% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for CORT is significantly above the industry average of 12.85%.
The last Return On Invested Capital (8.69%) for CORT is well below the 3 year average (17.94%), which needs to be investigated, but indicates that CORT had better years and this may not be a problem.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROIC | 8.69% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
1.3 Margins
CORT has a better Profit Margin (14.32%) than 86.39% of its industry peers.
In the last couple of years the Profit Margin of CORT has declined.
CORT has a Operating Margin of 8.85%. This is amongst the best in the industry. CORT outperforms 80.63% of its industry peers.
In the last couple of years the Operating Margin of CORT has declined.
Looking at the Gross Margin, with a value of 98.19%, CORT belongs to the top of the industry, outperforming 96.86% of the companies in the same industry.
CORT's Gross Margin has been stable in the last couple of years.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% |
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), CORT is creating value.
The number of shares outstanding for CORT has been increased compared to 1 year ago.
The number of shares outstanding for CORT has been reduced compared to 5 years ago.
CORT has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
2.2 Solvency
An Altman-Z score of 14.21 indicates that CORT is not in any danger for bankruptcy at the moment.
With an excellent Altman-Z score value of 14.21, CORT belongs to the best of the industry, outperforming 84.29% of the companies in the same industry.
There is no outstanding debt for CORT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 14.21 |
ROIC/WACC0.93
WACC9.37%
2.3 Liquidity
CORT has a Current Ratio of 3.14. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT has a Current ratio (3.14) which is in line with its industry peers.
CORT has a Quick Ratio of 3.07. This indicates that CORT is financially healthy and has no problem in meeting its short term obligations.
CORT has a Quick ratio (3.07) which is comparable to the rest of the industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 |
3. Growth
3.1 Past
CORT shows a strong negative growth in Earnings Per Share. In the last year the EPS decreased by -30.16%.
Measured over the past years, CORT shows a quite strong growth in Earnings Per Share. The EPS has been growing by 9.71% on average per year.
Looking at the last year, CORT shows a quite strong growth in Revenue. The Revenue has grown by 17.92% in the last year.
Measured over the past years, CORT shows a quite strong growth in Revenue. The Revenue has been growing by 17.11% on average per year.
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
3.2 Future
Based on estimates for the next years, CORT will show a very strong growth in Earnings Per Share. The EPS will grow by 54.42% on average per year.
CORT is expected to show a strong growth in Revenue. In the coming years, the Revenue will grow by 31.49% yearly.
EPS Next Y-20.21%
EPS Next 2Y-5.85%
EPS Next 3Y54.32%
EPS Next 5Y54.42%
Revenue Next Year18.44%
Revenue Next 2Y30.32%
Revenue Next 3Y30.85%
Revenue Next 5Y31.49%
3.3 Evolution
When comparing the EPS growth rate of the last years to the growth rate of the upcoming years, we see that the growth is accelerating.
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 43.41, which means the current valuation is very expensive for CORT.
Compared to the rest of the industry, the Price/Earnings ratio of CORT indicates a somewhat cheap valuation: CORT is cheaper than 77.49% of the companies listed in the same industry.
Compared to an average S&P500 Price/Earnings ratio of 26.60, CORT is valued quite expensively.
CORT is valuated quite expensively with a Price/Forward Earnings ratio of 34.76.
CORT's Price/Forward Earnings ratio is a bit cheaper when compared to the industry. CORT is cheaper than 72.25% of the companies in the same industry.
CORT is valuated rather expensively when we compare the Price/Forward Earnings ratio to 23.23, which is the current average of the S&P500 Index.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.41 | ||
| Fwd PE | 34.76 |
4.2 Price Multiples
CORT's Enterprise Value to EBITDA ratio is a bit cheaper when compared to the industry. CORT is cheaper than 77.49% of the companies in the same industry.
Based on the Price/Free Cash Flow ratio, CORT is valued cheaply inside the industry as 83.77% of the companies are valued more expensively.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 24.72 | ||
| EV/EBITDA | 44.27 |
4.3 Compensation for Growth
CORT has an outstanding profitability rating, which may justify a higher PE ratio.
A more expensive valuation may be justified as CORT's earnings are expected to grow with 54.32% in the coming years.
PEG (NY)N/A
PEG (5Y)4.47
EPS Next 2Y-5.85%
EPS Next 3Y54.32%
5. Dividend
5.1 Amount
CORT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
38.2
+3.4 (+9.77%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners75.62%
Inst Owner Change-1.11%
Ins Owners6.58%
Ins Owner Change-0.01%
Market Cap4.02B
Revenue(TTM)741.17M
Net Income(TTM)106.11M
Analysts80
Price Target129.72 (239.58%)
Short Float %10.88%
Short Ratio12.26
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)33.91%
Min EPS beat(2)16.19%
Max EPS beat(2)51.63%
EPS beat(4)3
Avg EPS beat(4)11.15%
Min EPS beat(4)-40.2%
Max EPS beat(4)51.63%
EPS beat(8)7
Avg EPS beat(8)17.67%
EPS beat(12)9
Avg EPS beat(12)13.54%
EPS beat(16)12
Avg EPS beat(16)12.14%
Revenue beat(2)0
Avg Revenue beat(2)-5.62%
Min Revenue beat(2)-6.85%
Max Revenue beat(2)-4.4%
Revenue beat(4)0
Avg Revenue beat(4)-8.72%
Min Revenue beat(4)-13.38%
Max Revenue beat(4)-4.4%
Revenue beat(8)4
Avg Revenue beat(8)-2.84%
Revenue beat(12)6
Avg Revenue beat(12)-1.78%
Revenue beat(16)7
Avg Revenue beat(16)-2.44%
PT rev (1m)-5.95%
PT rev (3m)-5.97%
EPS NQ rev (1m)-9.57%
EPS NQ rev (3m)-23.6%
EPS NY rev (1m)-2.76%
EPS NY rev (3m)-10.19%
Revenue NQ rev (1m)0.44%
Revenue NQ rev (3m)-9.98%
Revenue NY rev (1m)-3.79%
Revenue NY rev (3m)-5.21%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 43.41 | ||
| Fwd PE | 34.76 | ||
| P/S | 5.42 | ||
| P/FCF | 24.72 | ||
| P/OCF | 24.67 | ||
| P/B | 6.36 | ||
| P/tB | 6.36 | ||
| EV/EBITDA | 44.27 |
EPS(TTM)0.88
EY2.3%
EPS(NY)1.1
Fwd EY2.88%
FCF(TTM)1.55
FCFY4.05%
OCF(TTM)1.55
OCFY4.05%
SpS7.05
BVpS6.01
TBVpS6.01
PEG (NY)N/A
PEG (5Y)4.47
Graham Number10.91
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 12.88% | ||
| ROE | 16.79% | ||
| ROCE | 10.07% | ||
| ROIC | 8.69% | ||
| ROICexc | 24.92% | ||
| ROICexgc | 24.92% | ||
| OM | 8.85% | ||
| PM (TTM) | 14.32% | ||
| GM | 98.19% | ||
| FCFM | 21.93% |
ROA(3y)17.09%
ROA(5y)19.27%
ROE(3y)20.64%
ROE(5y)22.43%
ROIC(3y)17.94%
ROIC(5y)20.7%
ROICexc(3y)74.13%
ROICexc(5y)85.06%
ROICexgc(3y)74.13%
ROICexgc(5y)85.06%
ROCE(3y)20.79%
ROCE(5y)23.98%
ROICexgc growth 3Y-18.86%
ROICexgc growth 5Y-17.58%
ROICexc growth 3Y-18.86%
ROICexc growth 5Y-17.58%
OM growth 3Y-15.83%
OM growth 5Y-11.04%
PM growth 3Y-12.04%
PM growth 5Y-7.41%
GM growth 3Y-0.06%
GM growth 5Y0.04%
F-Score6
Asset Turnover0.9
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 36.2% | ||
| Cap/Sales | 0.04% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 245.43% | ||
| Profit Quality | 153.21% | ||
| Current Ratio | 3.14 | ||
| Quick Ratio | 3.07 | ||
| Altman-Z | 14.21 |
F-Score6
WACC9.37%
ROIC/WACC0.93
Cap/Depr(3y)112.18%
Cap/Depr(5y)124.4%
Cap/Sales(3y)0.15%
Cap/Sales(5y)0.19%
Profit Quality(3y)125.51%
Profit Quality(5y)133.52%
High Growth Momentum
Growth
EPS 1Y (TTM)-30.16%
EPS 3Y11.69%
EPS 5Y9.71%
EPS Q2Q%-60.98%
EPS Next Y-20.21%
EPS Next 2Y-5.85%
EPS Next 3Y54.32%
EPS Next 5Y54.42%
Revenue 1Y (TTM)17.92%
Revenue growth 3Y22.64%
Revenue growth 5Y17.11%
Sales Q2Q%13.75%
Revenue Next Year18.44%
Revenue Next 2Y30.32%
Revenue Next 3Y30.85%
Revenue Next 5Y31.49%
EBIT growth 1Y-54.26%
EBIT growth 3Y3.23%
EBIT growth 5Y4.18%
EBIT Next Year-24.4%
EBIT Next 3Y37.86%
EBIT Next 5Y19.15%
FCF growth 1Y5.22%
FCF growth 3Y5.38%
FCF growth 5Y7.73%
OCF growth 1Y5.34%
OCF growth 3Y5.66%
OCF growth 5Y7.79%
CORCEPT THERAPEUTICS INC / CORT FAQ
What is the ChartMill fundamental rating of CORCEPT THERAPEUTICS INC (CORT) stock?
ChartMill assigns a fundamental rating of 7 / 10 to CORT.
Can you provide the valuation status for CORCEPT THERAPEUTICS INC?
ChartMill assigns a valuation rating of 5 / 10 to CORCEPT THERAPEUTICS INC (CORT). This can be considered as Fairly Valued.
Can you provide the profitability details for CORCEPT THERAPEUTICS INC?
CORCEPT THERAPEUTICS INC (CORT) has a profitability rating of 8 / 10.
What are the PE and PB ratios of CORCEPT THERAPEUTICS INC (CORT) stock?
The Price/Earnings (PE) ratio for CORCEPT THERAPEUTICS INC (CORT) is 43.41 and the Price/Book (PB) ratio is 6.36.